Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposomal Bupivicaine (bupivacaine) (Pacira BioSciences, 0442e1)
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Percutaneous
01
Overview
Liposomal bupivacaine is an extended-release formulation of the amide-type local anesthetic bupivacaine. It utilizes the DepoFoam delivery system, which consists of multivesicular liposomes that encapsulate the drug and release it slowly over time, providing prolonged analgesia (up to 72 hours) compared to standard bupivacaine HCl. It works by binding to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing the generation and conduction of nerve impulses. It is primarily used for postsurgical local infiltration and regional nerve blocks to manage postoperative pain.
- Brand names
- Exparel
- Other names
- Liposomal bupivacaineBupivacaine liposome injectable suspensionLiposomal bupivicaine
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SCN5A (Sodium channel protein type 5 subunit alpha)Kir (Inward-rectifier potassium channels)KCNH2 (Voltage-gated potassium channel subfamily H member 2)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Liposomal Bupivicaine (bupivacaine) (Pacira BioSciences, 0442e1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liposomal Bupivicaine (bupivacaine) (Pacira BioSciences, 0442e1).